Umbilical Cord MSC Therapy for Core Autism Symptoms
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Autism Spectrum Disorder (ASD) are primarily supportive and focus on managing co-morbid symptoms, lacking disease-modifying therapies that address core symptoms, and there is a need for novel, effective treatments targeting immune dysregulation and abnormal neuronal connectivity.
Innovation Solution
Administration of human allogeneic umbilical cord tissue-derived mesenchymal stromal cells (hCT-MSCs) to modulate inflammatory processes in the brain, administered systemically, particularly via intravenous infusion, to treat ASD.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current supportive treatments (medication, behavioral therapy) are used to manage ASD, then co-morbid symptoms can be controlled, but core ASD symptoms remain unaddressed and individuals require lifelong support
Solution Approach 1:
The patent introduces mesenchymal stromal cells as an intermediary therapeutic agent that mediates immune modulation and neuroprotection. These cells act as a bridge between the immune system and neural tissue, addressing core ASD pathology through immunomodulation rather than merely managing symptoms. The MSCs secretome serves as a mediator that delivers trophic factors and anti-inflammatory molecules to affected brain regions.
Solution Approach 2:
The patent changes the fundamental parameter of treatment approach from symptomatic management to disease-modifying therapy. By administering mesenchymal stromal cells, the treatment targets the underlying immune dysregulation and neuroinflammation parameters that drive core ASD symptoms, rather than only addressing behavioral manifestations. This shifts the therapeutic paradigm from supportive care to potential cure.
2Reliability
If allogeneic hCT-MSCs are administered systemically via intravenous infusion, then the treatment can reach brain tissue and modulate inflammatory processes, but the complexity of cell therapy administration increases
Solution Approach 1:
The patent uses the bloodstream as an intermediary delivery system to transport mesenchymal stromal cells from the peripheral administration site to the central nervous system. The cells utilize the circulatory system as a conduit to reach brain tissue, avoiding the need for direct intracranial injection while still achieving therapeutic delivery to the target organ.
Solution Approach 2:
The patent employs a universal administration route (intravenous infusion) that can deliver therapeutic cells to the brain through the circulatory system. This multi-functional approach allows the same administration method to serve both as a delivery vehicle for cells and as a route for systemic distribution, simplifying the overall treatment protocol despite the complexity of cell therapy.
3Reliability
If early intensive behavioral intervention is provided to improve outcomes, then substantial improvement can be achieved, but the treatment is time-consuming and requires significant resource commitment
Solution Approach 1:
The patent administers mesenchymal stromal cells during a critical early window of neurodevelopment (ages 2-6 years), before extensive behavioral intervention is required. By addressing the underlying immune and inflammatory pathology early, the treatment creates a more favorable neural environment that may reduce the intensity and duration of subsequent behavioral therapy needs, performing the disease-modifying action before symptomatic management begins.
Solution Approach 2:
The patent introduces mesenchymal stromal cells as an intermediary that accelerates the therapeutic process by directly modifying disease pathology. Rather than relying solely on prolonged behavioral intervention to gradually improve outcomes, the MSCs serve as a catalyst that creates favorable neural conditions more quickly, potentially reducing the overall treatment timeline and resource commitment required.
Data Source
AI summary
The present disclosure provides methods of treating Autism Spectrum Disorder. More particularly, the present disclosure relates to methods of using cord blood tissue-derived mesenchymal stromal cells (hCT-MSCs) to treat Autism Spectrum Disorder. The methods involve treating a patient having or suspected of having an Autism Spectrum Disorder by administering a therapeutically effective amount of hCT-MSCs.